FDA approves Bayer's Sunharbo to cut repeat stroke risk

The FDA has approved Bayer's Sunharbo, a new blood thinner targeting clotting protein Factor XI, reducing repeat stroke risk by 26% in patients with non-cardiac clot-caused strokes. Unlike older anticoagulants, it lowers bleeding risk. Priced at $748.50/month, analysts project up to $4.5 billion in annual revenue, though insurance coverage remains uncertain.